Abstract | OBJECTIVE: This study evaluates the effect of intravaginal estriol on urogenital atrophy, Pap smear parameters, colposcopy parameters and discomfort during gynecological examination. METHODS: 31 postmenopausal women who had not used hormone therapy in the previous six months were studied. All women used intravaginal estriol, 1 mg/day for 21 days. The following variables were analyzed before and after treatment: complaints of urogenital atrophy; cytological parameters, colposcopic parameters, and subjective evaluation of discomfort during gynecologic examination. RESULTS: All urogenital atrophy complaints improved after treatment. At the first visit, 45.2% of women presented a predominance of profound cells, 51.6% with predominance of intermediate cells, and 3.2% with predominance of superficial cells. At the second visit, these rates were 35.5%, 64.5%, and 0%, respectively. Evaluation of the maturation index showed that 83.9% of women had atrophic Pap smears, and 16.1% showed good estrogenic level before treatment. At the second visit, atrophic smears occurred in 12.9%, and 87.1% of women exhibited good estrogenic level (chi2 = 20.045; p = 0.000). Colposcopy showed that 71% of women had atrophic colpitis and/or petequiae before treatment, while atrophy after therapy was present in only 6.4%. The evaluation of other colposcopic parameters also improved after treatment. Great discomfort was reported by 19.4% before and by 0% after treatment. CONCLUSION: Intravaginal estriol 1 mg/day for a period of 21 days was efficient in improving urogenital atrophy, Pap smear parameters and colposcopic evaluation in postmenopausal women.
|
Authors | A C S Chuery, N M de Góis Speck, K F Q de Moura, P N Belfort, C Sakano, J C L Ribalta |
Journal | Clinical and experimental obstetrics & gynecology
(Clin Exp Obstet Gynecol)
Vol. 38
Issue 2
Pg. 143-5
( 2011)
ISSN: 0390-6663 [Print] Singapore |
PMID | 21793275
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Administration, Intravaginal
- Aged
- Atrophy
(drug therapy)
- Estriol
(administration & dosage, pharmacology, therapeutic use)
- Female
- Female Urogenital Diseases
(drug therapy)
- Humans
- Middle Aged
- Postmenopause
(drug effects)
- Treatment Outcome
- Urogenital System
(pathology)
- Vagina
(drug effects, pathology)
|